Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.71 |
| ▸ | AGXT | P21549 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL28674174 | 0.98 | LOXL2 (0.69) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL5776752 | 0.89 | LOXL2 (0.67) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL9826461 | 0.87 | LOXL2 (0.65) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL7796043 | 0.85 | LOXL2 (0.62) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL533908 | 0.83 | LOXL2 (1.00) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| Hydrochloric Acid SCHEMBL6942058 | 0.82 | LOXL2 (0.96) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL9037490 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL6013090 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1ACYP19A1 | |
| SCHEMBL2249038 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1AFLT3 | |
| SCHEMBL4049122 | 0.80 | LOXL2 (0.60) | LOXL2AGXTHTR2BHTR1AFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| WO-2018048930-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| EP-2802608-A2 | COMPOUNDS&METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS&OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | Yale University (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8883824-B2 | 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013106646-A2 | COMPOUNDS AND METHODS FOR THE INHIBITION OF VCB E3 UBIQUITIN LIGASE | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106643-A2 | COMPOUNDS & METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS & OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | YALE UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-6063810-A | ENANTIOMORPHS | SYNTHELABO (FR) | 2000-05-16 | — | — | US | disclosed |
| US-6063810-A | ENANTIOMORPHS | SYNTHELABO (FR) | 2000-05-16 | — | — | US | disclosed |
| EP-0888324-A1 | 2-AMINOETHYL-BENZOFURAN DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032870-A1 | 2-AMINOETHYL-BENZOFURAN DERIVATIVES, PREPARATION THEREOF AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-09-12 | — | — | WO | disclosed |
| US-4932998-A | LOW PHYTOTOXICITY FOR PADDY RICE PLANTS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0283522-A1 | TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0009780-B1 | OCTAHYDRO-1H-BENZO(4,5)FURO(3,2-E)ISOQUINOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4260761-A | Intermediates for the preparation of octahydro-1H-benzo[4,5]furo[3,2,-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4243668-A | Octahydro-1H-benzo[4,5]furo[3,2-e]-isoquinoline analgesic and narcotic antagonistic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0009780-A2 | Octahydro-1H-benzo(4,5)furo(3,2-e)isoquinoline derivatives, process for their preparation and pharmaceutical compositions containing them | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | LOXL2 3764/4885AGXT 4438/4885HTR2B 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.